{
  "run_id": "db0dce33-c863-43cd-aa4c-ae2a8615c316",
  "prompt_variant_id": "4dc2854f-16a3-4017-ade3-1ec5e0f5bb4d",
  "api_config_name": "model_deepseek_chat",
  "test_case_id": "breast_cancer_her2_positive",
  "start_time": "2025-09-01T13:50:55.331250",
  "end_time": "2025-09-01T13:52:16.203493",
  "duration_ms": 80854.29573059082,
  "success": true,
  "error_message": "",
  "entities_extracted": 26,
  "entities_mapped": 21,
  "extraction_completeness": 1.625,
  "mapping_accuracy": 0.56,
  "precision": 0.5357142857142857,
  "recall": 0.9375,
  "f1_score": 0.6818181818181818,
  "compliance_score": 1.0,
  "token_usage": 12301,
  "extracted_entities": [
    {
      "text": "HER2-Positive Breast Cancer",
      "type": "condition",
      "attributes": {
        "status": "positive",
        "value": null,
        "unit": null,
        "temporal_context": null
      },
      "confidence": 1.0,
      "source_context": {
        "section": "Conditions",
        "position": 0,
        "context_sentence": "Conditions: HER2-Positive Breast Cancer, Metastatic Breast Cancer",
        "section_name": "conditionsModule",
        "section_type": "conditions",
        "document_id": "unknown"
      }
    },
    {
      "text": "Metastatic Breast Cancer",
      "type": "condition",
      "attributes": {
        "status": "positive",
        "value": null,
        "unit": null,
        "temporal_context": null
      },
      "confidence": 1.0,
      "source_context": {
        "section": "Conditions",
        "position": 25,
        "context_sentence": "Conditions: HER2-Positive Breast Cancer, Metastatic Breast Cancer",
        "section_name": "conditionsModule",
        "section_type": "conditions",
        "document_id": "unknown"
      }
    },
    {
      "text": "Histologically confirmed HER2-positive metastatic breast cancer",
      "type": "condition",
      "attributes": {
        "status": "positive",
        "value": null,
        "unit": null,
        "temporal_context": "current"
      },
      "confidence": 1.0,
      "source_context": {
        "section": "INCLUSION CRITERIA",
        "position": "30-80",
        "context_sentence": "Histologically confirmed HER2-positive metastatic breast cancer",
        "section_name": "eligibilityModule",
        "section_type": "eligibility",
        "document_id": "unknown"
      }
    },
    {
      "text": "HER2-positive",
      "type": "biomarker",
      "attributes": {
        "status": "positive",
        "value": null,
        "unit": null,
        "temporal_context": "current"
      },
      "confidence": 1.0,
      "source_context": {
        "section": "INCLUSION CRITERIA",
        "position": "55-68",
        "context_sentence": "Histologically confirmed HER2-positive metastatic breast cancer",
        "section_name": "eligibilityModule",
        "section_type": "eligibility",
        "document_id": "unknown"
      }
    },
    {
      "text": "Measurable disease per RECIST 1.1",
      "type": "condition",
      "attributes": {
        "status": "positive",
        "value": null,
        "unit": null,
        "temporal_context": "current"
      },
      "confidence": 1.0,
      "source_context": {
        "section": "INCLUSION CRITERIA",
        "position": "82-112",
        "context_sentence": "Measurable disease per RECIST 1.1",
        "section_name": "eligibilityModule",
        "section_type": "eligibility",
        "document_id": "unknown"
      }
    },
    {
      "text": "RECIST 1.1",
      "type": "procedure",
      "attributes": {
        "status": "positive",
        "value": null,
        "unit": null,
        "temporal_context": "current"
      },
      "confidence": 1.0,
      "source_context": {
        "section": "INCLUSION CRITERIA",
        "position": "102-112",
        "context_sentence": "Measurable disease per RECIST 1.1",
        "section_name": "eligibilityModule",
        "section_type": "eligibility",
        "document_id": "unknown"
      }
    },
    {
      "text": "ECOG performance status 0-1",
      "type": "demographic",
      "attributes": {
        "status": "positive",
        "value": "0-1",
        "unit": null,
        "temporal_context": "current"
      },
      "confidence": 1.0,
      "source_context": {
        "section": "INCLUSION CRITERIA",
        "position": "114-140",
        "context_sentence": "ECOG performance status 0-1",
        "section_name": "eligibilityModule",
        "section_type": "eligibility",
        "document_id": "unknown"
      }
    },
    {
      "text": "Adequate organ function",
      "type": "condition",
      "attributes": {
        "status": "positive",
        "value": null,
        "unit": null,
        "temporal_context": "current"
      },
      "confidence": 1.0,
      "source_context": {
        "section": "INCLUSION CRITERIA",
        "position": "142-164",
        "context_sentence": "Adequate organ function",
        "section_name": "eligibilityModule",
        "section_type": "eligibility",
        "document_id": "unknown"
      }
    },
    {
      "text": "Prior treatment with Trastuzumab Deruxtecan",
      "type": "exclusion",
      "attributes": {
        "status": "negative",
        "value": null,
        "unit": null,
        "temporal_context": "past"
      },
      "confidence": 1.0,
      "source_context": {
        "section": "EXCLUSION CRITERIA",
        "position": "180-220",
        "context_sentence": "Prior treatment with Trastuzumab Deruxtecan",
        "section_name": "eligibilityModule",
        "section_type": "eligibility",
        "document_id": "unknown"
      }
    },
    {
      "text": "Trastuzumab Deruxtecan",
      "type": "medication",
      "attributes": {
        "status": "negative",
        "value": null,
        "unit": null,
        "temporal_context": "past"
      },
      "confidence": 1.0,
      "source_context": {
        "section": "EXCLUSION CRITERIA",
        "position": "200-220",
        "context_sentence": "Prior treatment with Trastuzumab Deruxtecan",
        "section_name": "eligibilityModule",
        "section_type": "eligibility",
        "document_id": "unknown"
      }
    },
    {
      "text": "Active brain metastases",
      "type": "exclusion",
      "attributes": {
        "status": "negative",
        "value": null,
        "unit": null,
        "temporal_context": "current"
      },
      "confidence": 1.0,
      "source_context": {
        "section": "EXCLUSION CRITERIA",
        "position": "222-244",
        "context_sentence": "Active brain metastases",
        "section_name": "eligibilityModule",
        "section_type": "eligibility",
        "document_id": "unknown"
      }
    },
    {
      "text": "brain metastases",
      "type": "condition",
      "attributes": {
        "status": "negative",
        "value": null,
        "unit": null,
        "temporal_context": "current"
      },
      "confidence": 1.0,
      "source_context": {
        "section": "EXCLUSION CRITERIA",
        "position": "229-244",
        "context_sentence": "Active brain metastases",
        "section_name": "eligibilityModule",
        "section_type": "eligibility",
        "document_id": "unknown"
      }
    },
    {
      "text": "Pregnancy or breastfeeding",
      "type": "exclusion",
      "attributes": {
        "status": "negative",
        "value": null,
        "unit": null,
        "temporal_context": "current"
      },
      "confidence": 1.0,
      "source_context": {
        "section": "EXCLUSION CRITERIA",
        "position": "246-270",
        "context_sentence": "Pregnancy or breastfeeding",
        "section_name": "eligibilityModule",
        "section_type": "eligibility",
        "document_id": "unknown"
      }
    },
    {
      "text": "Pregnancy",
      "type": "condition",
      "attributes": {
        "status": "negative",
        "value": null,
        "unit": null,
        "temporal_context": "current"
      },
      "confidence": 1.0,
      "source_context": {
        "section": "EXCLUSION CRITERIA",
        "position": "246-255",
        "context_sentence": "Pregnancy or breastfeeding",
        "section_name": "eligibilityModule",
        "section_type": "eligibility",
        "document_id": "unknown"
      }
    },
    {
      "text": "breastfeeding",
      "type": "condition",
      "attributes": {
        "status": "negative",
        "value": null,
        "unit": null,
        "temporal_context": "current"
      },
      "confidence": 1.0,
      "source_context": {
        "section": "EXCLUSION CRITERIA",
        "position": "259-270",
        "context_sentence": "Pregnancy or breastfeeding",
        "section_name": "eligibilityModule",
        "section_type": "eligibility",
        "document_id": "unknown"
      }
    },
    {
      "text": "HER2-targeted therapy",
      "type": "medication",
      "attributes": {
        "status": "positive",
        "value": null,
        "unit": null,
        "temporal_context": "current"
      },
      "confidence": 0.9,
      "source_context": {
        "section": "briefSummary",
        "position": 20,
        "context_sentence": "This study evaluates a novel HER2-targeted therapy in patients with HER2-positive metastatic breast cancer who have progressed on prior trastuzumab-based therapy.",
        "section_name": "descriptionModule",
        "section_type": "description",
        "document_id": "unknown"
      }
    },
    {
      "text": "HER2-positive",
      "type": "biomarker",
      "attributes": {
        "status": "positive",
        "value": null,
        "unit": null,
        "temporal_context": "current"
      },
      "confidence": 1.0,
      "source_context": {
        "section": "briefSummary",
        "position": 60,
        "context_sentence": "This study evaluates a novel HER2-targeted therapy in patients with HER2-positive metastatic breast cancer who have progressed on prior trastuzumab-based therapy.",
        "section_name": "descriptionModule",
        "section_type": "description",
        "document_id": "unknown"
      }
    },
    {
      "text": "metastatic breast cancer",
      "type": "condition",
      "attributes": {
        "status": "positive",
        "value": null,
        "unit": null,
        "temporal_context": "current"
      },
      "confidence": 1.0,
      "source_context": {
        "section": "briefSummary",
        "position": 75,
        "context_sentence": "This study evaluates a novel HER2-targeted therapy in patients with HER2-positive metastatic breast cancer who have progressed on prior trastuzumab-based therapy.",
        "section_name": "descriptionModule",
        "section_type": "description",
        "document_id": "unknown"
      }
    },
    {
      "text": "progressed",
      "type": "condition",
      "attributes": {
        "status": "positive",
        "value": null,
        "unit": null,
        "temporal_context": "past"
      },
      "confidence": 0.9,
      "source_context": {
        "section": "briefSummary",
        "position": 95,
        "context_sentence": "This study evaluates a novel HER2-targeted therapy in patients with HER2-positive metastatic breast cancer who have progressed on prior trastuzumab-based therapy.",
        "section_name": "descriptionModule",
        "section_type": "description",
        "document_id": "unknown"
      }
    },
    {
      "text": "trastuzumab-based therapy",
      "type": "medication",
      "attributes": {
        "status": "positive",
        "value": null,
        "unit": null,
        "temporal_context": "past"
      },
      "confidence": 0.9,
      "source_context": {
        "section": "briefSummary",
        "position": 115,
        "context_sentence": "This study evaluates a novel HER2-targeted therapy in patients with HER2-positive metastatic breast cancer who have progressed on prior trastuzumab-based therapy.",
        "section_name": "descriptionModule",
        "section_type": "description",
        "document_id": "unknown"
      }
    },
    {
      "text": "HER2-Positive",
      "type": "biomarker",
      "attributes": {
        "status": "positive",
        "value": null,
        "unit": null,
        "temporal_context": "current"
      },
      "confidence": 1.0,
      "source_context": {
        "section": "briefTitle",
        "position": "20-32",
        "context_sentence": "Study of Novel Therapy in HER2-Positive Breast Cancer",
        "section_name": "identificationModule",
        "section_type": "identification",
        "document_id": "unknown"
      }
    },
    {
      "text": "Breast Cancer",
      "type": "condition",
      "attributes": {
        "status": "positive",
        "value": null,
        "unit": null,
        "temporal_context": "current"
      },
      "confidence": 1.0,
      "source_context": {
        "section": "briefTitle",
        "position": "33-45",
        "context_sentence": "Study of Novel Therapy in HER2-Positive Breast Cancer",
        "section_name": "identificationModule",
        "section_type": "identification",
        "document_id": "unknown"
      }
    },
    {
      "text": "HER2-Positive",
      "type": "biomarker",
      "attributes": {
        "status": "positive",
        "value": null,
        "unit": null,
        "temporal_context": "current"
      },
      "confidence": 1.0,
      "source_context": {
        "section": "officialTitle",
        "position": "40-52",
        "context_sentence": "A Phase III Study of Novel Targeted Therapy in HER2-Positive Metastatic Breast Cancer",
        "section_name": "identificationModule",
        "section_type": "identification",
        "document_id": "unknown"
      }
    },
    {
      "text": "Metastatic",
      "type": "condition",
      "attributes": {
        "status": "positive",
        "value": null,
        "unit": null,
        "temporal_context": "current"
      },
      "confidence": 1.0,
      "source_context": {
        "section": "officialTitle",
        "position": "53-63",
        "context_sentence": "A Phase III Study of Novel Targeted Therapy in HER2-Positive Metastatic Breast Cancer",
        "section_name": "identificationModule",
        "section_type": "identification",
        "document_id": "unknown"
      }
    },
    {
      "text": "Breast Cancer",
      "type": "condition",
      "attributes": {
        "status": "positive",
        "value": null,
        "unit": null,
        "temporal_context": "current"
      },
      "confidence": 1.0,
      "source_context": {
        "section": "officialTitle",
        "position": "64-76",
        "context_sentence": "A Phase III Study of Novel Targeted Therapy in HER2-Positive Metastatic Breast Cancer",
        "section_name": "identificationModule",
        "section_type": "identification",
        "document_id": "unknown"
      }
    },
    {
      "text": "Phase III",
      "type": "temporal",
      "attributes": {
        "status": null,
        "value": "III",
        "unit": "phase",
        "temporal_context": "current"
      },
      "confidence": 1.0,
      "source_context": {
        "section": "officialTitle",
        "position": "10-18",
        "context_sentence": "A Phase III Study of Novel Targeted Therapy in HER2-Positive Metastatic Breast Cancer",
        "section_name": "identificationModule",
        "section_type": "identification",
        "document_id": "unknown"
      }
    }
  ],
  "mcode_mappings": [
    {
      "resourceType": "Condition",
      "mcode_element": "CancerCondition",
      "code": {
        "system": "http://hl7.org/fhir/us/mcode",
        "code": "cancercondition",
        "display": "CancerCondition"
      },
      "value": "HER2-positive breast cancer",
      "mapping_confidence": 1.0,
      "source_text_fragment": "Entity index 0",
      "mapping_rationale": "Direct mapping to cancer condition with HER2 biomarker status",
      "id": "4ae10d7d-0465-42cb-89d8-0f7069314890",
      "llm_source_text_fragment": "Entity index 0",
      "source_references": []
    },
    {
      "resourceType": "Condition",
      "mcode_element": "CancerCondition",
      "code": {
        "system": "http://hl7.org/fhir/us/mcode",
        "code": "cancercondition",
        "display": "CancerCondition"
      },
      "value": "Metastatic breast cancer",
      "mapping_confidence": 1.0,
      "source_text_fragment": "Entity index 1",
      "mapping_rationale": "Direct mapping to metastatic cancer condition",
      "id": "62ceeb9e-8c8d-46bc-9b9a-6ee990675471",
      "llm_source_text_fragment": "Entity index 1",
      "source_references": []
    },
    {
      "resourceType": "Condition",
      "mcode_element": "CancerCondition",
      "code": {
        "system": "http://hl7.org/fhir/us/mcode",
        "code": "cancercondition",
        "display": "CancerCondition"
      },
      "value": "HER2-positive metastatic breast cancer",
      "mapping_confidence": 1.0,
      "source_text_fragment": "Entity index 2",
      "mapping_rationale": "Combined cancer condition with biomarker and metastatic status",
      "id": "9cb57fdb-65fa-442a-83ab-126fef665446",
      "llm_source_text_fragment": "Entity index 2",
      "source_references": []
    },
    {
      "resourceType": "Observation",
      "mcode_element": "GenomicVariant",
      "code": {
        "system": "http://hl7.org/fhir/us/mcode",
        "code": "genomicvariant",
        "display": "GenomicVariant"
      },
      "value": "HER2-positive",
      "mapping_confidence": 1.0,
      "source_text_fragment": "Entity index 3",
      "mapping_rationale": "HER2 biomarker status maps to genomic variant observation",
      "id": "4152fcb1-cd75-4c38-902c-2a1b90b73891",
      "llm_source_text_fragment": "Entity index 3",
      "source_references": []
    },
    {
      "resourceType": "Observation",
      "mcode_element": "CancerDiseaseStatus",
      "code": {
        "system": "http://hl7.org/fhir/us/mcode",
        "code": "cancerdiseasestatus",
        "display": "CancerDiseaseStatus"
      },
      "value": "active",
      "mapping_confidence": 0.8,
      "source_text_fragment": "Entity index 4",
      "mapping_rationale": "Measurable disease implies active disease status per RECIST criteria",
      "id": "c6783dc0-5ce2-4f71-9ec4-55445f110354",
      "llm_source_text_fragment": "Entity index 4",
      "source_references": []
    },
    {
      "resourceType": "Procedure",
      "mcode_element": "CancerRelatedProcedure",
      "code": {
        "system": "http://hl7.org/fhir/us/mcode",
        "code": "cancerrelatedprocedure",
        "display": "CancerRelatedProcedure"
      },
      "value": "RECIST 1.1 assessment",
      "mapping_confidence": 0.9,
      "source_text_fragment": "Entity index 5",
      "mapping_rationale": "RECIST 1.1 is a standardized cancer response assessment procedure",
      "id": "17ae8dbd-4eac-4a01-a03e-e857c98b9ab2",
      "llm_source_text_fragment": "Entity index 5",
      "source_references": []
    },
    {
      "resourceType": "Observation",
      "mcode_element": "ECOGPerformanceStatus",
      "code": {
        "system": "http://hl7.org/fhir/us/mcode",
        "code": "ecogperformancestatus",
        "display": "ECOGPerformanceStatus"
      },
      "value": "0-1",
      "mapping_confidence": 1.0,
      "source_text_fragment": "Entity index 6",
      "mapping_rationale": "Direct mapping to ECOG performance status score range",
      "id": "20858fee-72ed-490b-8845-b3dd200a4478",
      "llm_source_text_fragment": "Entity index 6",
      "source_references": []
    },
    {
      "resourceType": "MedicationStatement",
      "mcode_element": "CancerRelatedMedication",
      "code": {
        "system": "http://hl7.org/fhir/us/mcode",
        "code": "cancerrelatedmedication",
        "display": "CancerRelatedMedication"
      },
      "value": "Trastuzumab Deruxtecan",
      "mapping_confidence": 1.0,
      "source_text_fragment": "Entity index 8",
      "mapping_rationale": "HER2-targeted therapy medication with exclusion status",
      "id": "8ce0ce12-00a5-4802-89a5-dd0ad0a37e7e",
      "llm_source_text_fragment": "Entity index 8",
      "source_references": []
    },
    {
      "resourceType": "MedicationStatement",
      "mcode_element": "CancerRelatedMedication",
      "code": {
        "system": "http://hl7.org/fhir/us/mcode",
        "code": "cancerrelatedmedication",
        "display": "CancerRelatedMedication"
      },
      "value": "Trastuzumab Deruxtecan",
      "mapping_confidence": 1.0,
      "source_text_fragment": "Entity index 9",
      "mapping_rationale": "Specific HER2-targeted therapy medication",
      "id": "d0223298-c67a-4fd3-8d0c-477596860b35",
      "llm_source_text_fragment": "Entity index 9",
      "source_references": []
    },
    {
      "resourceType": "Condition",
      "mcode_element": "CancerCondition",
      "code": {
        "system": "http://hl7.org/fhir/us/mcode",
        "code": "cancercondition",
        "display": "CancerCondition"
      },
      "value": "Brain metastases",
      "mapping_confidence": 0.9,
      "source_text_fragment": "Entity index 10",
      "mapping_rationale": "Metastatic cancer condition with exclusion status",
      "id": "27956dae-461f-41f1-a429-6824427d56ba",
      "llm_source_text_fragment": "Entity index 10",
      "source_references": []
    },
    {
      "resourceType": "Condition",
      "mcode_element": "CancerCondition",
      "code": {
        "system": "http://hl7.org/fhir/us/mcode",
        "code": "cancercondition",
        "display": "CancerCondition"
      },
      "value": "Brain metastases",
      "mapping_confidence": 0.9,
      "source_text_fragment": "Entity index 11",
      "mapping_rationale": "Metastatic cancer condition",
      "id": "46c7b665-ef2e-4b6e-aefe-a1bad9eedbc4",
      "llm_source_text_fragment": "Entity index 11",
      "source_references": []
    },
    {
      "resourceType": "MedicationStatement",
      "mcode_element": "CancerRelatedMedication",
      "code": {
        "system": "http://hl7.org/fhir/us/mcode",
        "code": "cancerrelatedmedication",
        "display": "CancerRelatedMedication"
      },
      "value": "HER2-targeted therapy",
      "mapping_confidence": 0.9,
      "source_text_fragment": "Entity index 15",
      "mapping_rationale": "Class of HER2-targeted cancer medications",
      "id": "a50f7310-d424-4ecf-abe5-933a276c5a7b",
      "llm_source_text_fragment": "Entity index 15",
      "source_references": []
    },
    {
      "resourceType": "Observation",
      "mcode_element": "GenomicVariant",
      "code": {
        "system": "http://hl7.org/fhir/us/mcode",
        "code": "genomicvariant",
        "display": "GenomicVariant"
      },
      "value": "HER2-positive",
      "mapping_confidence": 1.0,
      "source_text_fragment": "Entity index 16",
      "mapping_rationale": "HER2 biomarker status maps to genomic variant observation",
      "id": "fb035315-1d83-404a-a83d-d2d09e730e69",
      "llm_source_text_fragment": "Entity index 16",
      "source_references": []
    },
    {
      "resourceType": "Condition",
      "mcode_element": "CancerCondition",
      "code": {
        "system": "http://hl7.org/fhir/us/mcode",
        "code": "cancercondition",
        "display": "CancerCondition"
      },
      "value": "Metastatic breast cancer",
      "mapping_confidence": 1.0,
      "source_text_fragment": "Entity index 17",
      "mapping_rationale": "Metastatic cancer condition",
      "id": "f490fbeb-f94e-4572-9954-d450f09a7ece",
      "llm_source_text_fragment": "Entity index 17",
      "source_references": []
    },
    {
      "resourceType": "Observation",
      "mcode_element": "CancerDiseaseStatus",
      "code": {
        "system": "http://hl7.org/fhir/us/mcode",
        "code": "cancerdiseasestatus",
        "display": "CancerDiseaseStatus"
      },
      "value": "progression",
      "mapping_confidence": 0.9,
      "source_text_fragment": "Entity index 18",
      "mapping_rationale": "Disease progression status from prior therapy",
      "id": "2dc91c98-900c-4492-8a12-7cfd47c5d29a",
      "llm_source_text_fragment": "Entity index 18",
      "source_references": []
    },
    {
      "resourceType": "MedicationStatement",
      "mcode_element": "CancerRelatedMedication",
      "code": {
        "system": "http://hl7.org/fhir/us/mcode",
        "code": "cancerrelatedmedication",
        "display": "CancerRelatedMedication"
      },
      "value": "Trastuzumab-based therapy",
      "mapping_confidence": 0.9,
      "source_text_fragment": "Entity index 19",
      "mapping_rationale": "Class of HER2-targeted cancer medications including trastuzumab",
      "id": "8bd23943-02d6-4a8d-bf2b-88ef5eb816fc",
      "llm_source_text_fragment": "Entity index 19",
      "source_references": []
    },
    {
      "resourceType": "Observation",
      "mcode_element": "GenomicVariant",
      "code": {
        "system": "http://hl7.org/fhir/us/mcode",
        "code": "genomicvariant",
        "display": "GenomicVariant"
      },
      "value": "HER2-positive",
      "mapping_confidence": 1.0,
      "source_text_fragment": "Entity index 20",
      "mapping_rationale": "HER2 biomarker status maps to genomic variant observation",
      "id": "dcb6d7aa-34ed-4dcc-bf3e-fae8af04c233",
      "llm_source_text_fragment": "Entity index 20",
      "source_references": []
    },
    {
      "resourceType": "Condition",
      "mcode_element": "CancerCondition",
      "code": {
        "system": "http://hl7.org/fhir/us/mcode",
        "code": "cancercondition",
        "display": "CancerCondition"
      },
      "value": "Breast cancer",
      "mapping_confidence": 1.0,
      "source_text_fragment": "Entity index 21",
      "mapping_rationale": "Primary cancer condition",
      "id": "da0b48fe-e85e-4bf6-9681-cebf6a00eefc",
      "llm_source_text_fragment": "Entity index 21",
      "source_references": []
    },
    {
      "resourceType": "Observation",
      "mcode_element": "GenomicVariant",
      "code": {
        "system": "http://hl7.org/fhir/us/mcode",
        "code": "genomicvariant",
        "display": "GenomicVariant"
      },
      "value": "HER2-positive",
      "mapping_confidence": 1.0,
      "source_text_fragment": "Entity index 22",
      "mapping_rationale": "HER2 biomarker status maps to genomic variant observation",
      "id": "84566c02-9bb7-4162-928d-8cc8aa250d23",
      "llm_source_text_fragment": "Entity index 22",
      "source_references": []
    },
    {
      "resourceType": "Condition",
      "mcode_element": "CancerCondition",
      "code": {
        "system": "http://hl7.org/fhir/us/mcode",
        "code": "cancercondition",
        "display": "CancerCondition"
      },
      "value": "Metastatic",
      "mapping_confidence": 0.8,
      "source_text_fragment": "Entity index 23",
      "mapping_rationale": "Metastatic status modifier for cancer condition",
      "id": "421851d0-7643-4951-945b-1eed88b15ba7",
      "llm_source_text_fragment": "Entity index 23",
      "source_references": []
    },
    {
      "resourceType": "Condition",
      "mcode_element": "CancerCondition",
      "code": {
        "system": "http://hl7.org/fhir/us/mcode",
        "code": "cancercondition",
        "display": "CancerCondition"
      },
      "value": "Breast cancer",
      "mapping_confidence": 1.0,
      "source_text_fragment": "Entity index 24",
      "mapping_rationale": "Primary cancer condition",
      "id": "dbc9b260-6439-4e4b-97b1-4905d0aed060",
      "llm_source_text_fragment": "Entity index 24",
      "source_references": []
    }
  ],
  "validation_results": {
    "valid": true,
    "errors": [],
    "warnings": [],
    "compliance_score": 1.0
  }
}